Rep. James Comer (R-KY) (Tom Williams/CQ Roll Call via AP Images)
July 23, 2024 03:27 PM EDTUpdated 03:49 PM
Pharma
Law

PBM ex­ec­u­tives dodge grilling in House com­mit­tee hear­ing

Zachary Brennan

Senior Editor

Chief ex­ec­u­tives from the three largest phar­ma­cy ben­e­fit man­agers (PBMs) steered around most of the dif­fi­cult ques­tions at a con­gres­sion­al hear­ing, re­peat­ed­ly blam­ing ris­ing pre­scrip­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times